M S, S S
Adv Pharmacol Pharm Sci. 2025; 2024():5248746.
PMID: 39781028
PMC: 11707065.
DOI: 10.1155/2024/5248746.
Chadwick D, Barker F, Smith C, Perditer O, Hardy Y, Owusu D
BMC Nephrol. 2024; 25(1):241.
PMID: 39075393
PMC: 11288112.
DOI: 10.1186/s12882-024-03537-7.
Safdar S, Shahrukh S, Khan A, Shahid Z
Cureus. 2022; 14(8):e28205.
PMID: 36158425
PMC: 9484585.
DOI: 10.7759/cureus.28205.
Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H
Curr Top Med Chem. 2019; 19(18):1621-1649.
PMID: 31424371
PMC: 7132033.
DOI: 10.2174/1568026619666190712204603.
Boswell M, Rossouw T
South Afr J HIV Med. 2018; 18(1):714.
PMID: 29568636
PMC: 5843257.
DOI: 10.4102/sajhivmed.v18i1.714.
Effect of tenofovir on renal function in patients with chronic hepatitis B.
Jung W, Jang J, Park W, Jeong S, Lee H, Park S
Medicine (Baltimore). 2018; 97(7):e9756.
PMID: 29443737
PMC: 5839852.
DOI: 10.1097/MD.0000000000009756.
Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study.
Tsai M, Chen C, Tseng P, Hung C, Chiu K, Chang K
PLoS One. 2016; 11(3):e0149761.
PMID: 26964034
PMC: 4786133.
DOI: 10.1371/journal.pone.0149761.
Drug-Induced Metabolic Acidosis.
Pham A, Richie Xu L, Moe O
F1000Res. 2016; 4.
PMID: 26918138
PMC: 4754009.
DOI: 10.12688/f1000research.7006.1.
Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.
Chadwick D, Sarfo F, Kirk E, Owusu D, Bedu-Addo G, Parris V
BMC Nephrol. 2015; 16:195.
PMID: 26627687
PMC: 4666076.
DOI: 10.1186/s12882-015-0192-4.
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.
Ustianowski A, Arends J
Infect Dis Ther. 2015; 4(2):145-57.
PMID: 26032649
PMC: 4471058.
DOI: 10.1007/s40121-015-0070-1.
Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.
Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R
Medicine (Baltimore). 2015; 94(15):e646.
PMID: 25881837
PMC: 4602512.
DOI: 10.1097/MD.0000000000000646.
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
Jafari A, Khalili H, Dashti-Khavidaki S
Eur J Clin Pharmacol. 2014; 70(9):1029-40.
PMID: 24958564
DOI: 10.1007/s00228-014-1712-z.
Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.
Pandey K
HIV AIDS (Auckl). 2014; 6:81-90.
PMID: 24876793
PMC: 4037326.
DOI: 10.2147/HIV.S39178.
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C
J Infect Dis. 2014; 210(3):363-73.
PMID: 24585896
PMC: 4091582.
DOI: 10.1093/infdis/jiu107.
Proteinuria in paediatric patients with human immunodeficiency virus infection.
Giacomet V, Erba P, Di Nello F, Coletto S, Vigano A, Zuccotti G
World J Clin Cases. 2013; 1(1):13-8.
PMID: 24303454
PMC: 3845933.
DOI: 10.12998/wjcc.v1.i1.13.
Differences in Serum Levels of Magnesium, Phosphate, and Albumin for HAART-Experienced and HAART-Naïve Female Patients Attending Parirenyatwa Opportunistic Infections Clinic in Harare, Zimbabwe.
Mudzinge D, Nyazika T, Chisango T, Zhou D
ISRN AIDS. 2013; 2013:383214.
PMID: 24093073
PMC: 3777213.
DOI: 10.1155/2013/383214.
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.
Kebodeaux C, Garavaglia Wilson A, Smith D, Vouri S
HIV AIDS (Auckl). 2013; 5:263-74.
PMID: 24068878
PMC: 3782510.
DOI: 10.2147/HIV.S36311.
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?.
Tourret J, Deray G, Isnard-Bagnis C
J Am Soc Nephrol. 2013; 24(10):1519-27.
PMID: 24052632
PMC: 3785270.
DOI: 10.1681/ASN.2012080857.
Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney.
Abraham P, Ramamoorthy H, Isaac B
J Biomed Sci. 2013; 20:61.
PMID: 23957306
PMC: 3765371.
DOI: 10.1186/1423-0127-20-61.
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y
BMC Infect Dis. 2013; 13:301.
PMID: 23815472
PMC: 3707768.
DOI: 10.1186/1471-2334-13-301.